Compare UNB & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNB | ARMP |
|---|---|---|
| Founded | 1891 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 125.7M |
| IPO Year | 1998 | N/A |
| Metric | UNB | ARMP |
|---|---|---|
| Price | $24.49 | $7.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 17.7K | ★ 29.5K |
| Earning Date | 01-16-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.08% | N/A |
| EPS Growth | ★ 27.30 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $52,533,000.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.60 | ★ N/A |
| Revenue Growth | ★ 13.25 | N/A |
| 52 Week Low | $20.65 | $0.90 |
| 52 Week High | $36.00 | $16.34 |
| Indicator | UNB | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 63.27 | 64.63 |
| Support Level | $23.32 | $5.87 |
| Resistance Level | $24.32 | $6.60 |
| Average True Range (ATR) | 0.65 | 0.52 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 77.15 | 89.55 |
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.